Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.75 |
| ▸ | MAPT | P10636 | 7/20 | 0.75 |
| ▸ | LMNA | P02545 | 6/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881267 | 0.86 | ALDH1A1 (0.71) | ALDH1A1MAPTLMNAADORA1GAA | |
| SCHEMBL20280436 | 0.86 | ALDH1A1 (0.71) | ALDH1A1MAPTLMNAADORA1GAA | |
| SCHEMBL871700 | 0.86 | ALDH1A1 (0.71) | ALDH1A1MAPTLMNAADORA1GAA | |
| SCHEMBL18551034 | 0.86 | MAPT (0.71) | ALDH1A1MAPTLMNAADORA1GAA | |
| SCHEMBL1638729 | 0.86 | ALDH1A1 (1.00) | ALDH1A1MAPTLMNAADORA1GAA | |
| SCHEMBL7490234 | 0.85 | MAPT (0.69) | ALDH1A1MAPTLMNAADORA1GAA | |
| SCHEMBL21847260 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MAPTLMNAADORA1GAA | |
| SCHEMBL21847237 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MAPTLMNAADORA1GAA | |
| SCHEMBL133651 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNAADORA1GAA | |
| SCHEMBL133336 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNAADORA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3936507-A1 | COMPOUNDS HAVING BOTH EFFECTS OF BET BROMODOMAIN PROTEIN INHIBITION AND PD-L1 GENE REGULATION | Medshine Discovery Inc. (CN) | 2022-01-12 | — | — | EP | disclosed |
| WO-2018109053-A1 | PROCESS FOR THE MANUFACTURE OF DIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-21 | — | — | WO | disclosed |
| EP-2430029-B1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2018-01-10 | — | — | EP | disclosed |
| US-9499563-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-11-22 | — | — | US | disclosed |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2014-10-02 | — | — | US | disclosed |
| US-8785638-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-07-22 | — | — | US | disclosed |
| EP-2430029-A1 | THIENO [2, 3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-03-08 | — | — | US | disclosed |
| US-8044042-B2 | Thienotriazolodiazepine compound and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| WO-2010130842-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | ICOS, CD4, CD2 | ALDH1A1 2055/4885MAPT 2384/4885LMNA 4876/4885 |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | ALDH1A1 1925/4885MAPT 2061/4885LMNA 3907/4885 |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | ALDH1A1 1925/4885MAPT 2061/4885LMNA 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.